Abbreviations & Glossary
| Term | Description |
|---|---|
| ALCL | Anaplastic large-cell non-Hodgkin's lymphoma |
| AML | Acute myeloid leukemia |
| BME | β-mercaptoethanol |
| Ca | calcium |
| ChIP | Chromatin immunoprecipitation |
| CLIPTAC | Click-formed proteolysis targeting chimera |
| CLL | Lymphocytic leukemia |
| CML | Chronic myelogenous leukemia |
| CRPC | Castrationresistant prostate cancer |
| Cys | L-cystine |
| DC50 | 50% of degradation concentration |
| DMEM | Dulbecco's modification of Eagle's medium |
| DMSO | dimethyl sulfoxide |
| DPBS | Dulbecco's phosphate buffered saline |
| EC50 | The molar concentration of an agonist that produces 50% of the maximum possible response for that agonist |
| ED50 | In vitro or in vivo dose of drug that produces 50% of its maximum response or effect |
| ELISA | Enzyme-linked immunosorbent assay |
| Ex vivo | Taking place outside a living organism |
| FBS | fetal bovine serum |
| FC | Flow cytometry |
| Glc | glucose |
| Gln | L-glutamine |
| HAT | hypoxanthine, aminopterin, thymidine |
| HBSS | Hank's balanced salt solution |
| HEPES | 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid |
| HT | hypoxanthine, thymidine |
| i.a. | Intra-arterial route of drug administration |
| IC50 | In a functional assay, the molar concentration of an agonist or antagonist which produces 50% of its maximum possible inhibition |
| i.c. | Intracerebral route of drug administration |
| ICC | Immunocytochemistry |
| i.c.v. | Intracerebroventricular route of drug administration |
| ID50 | In vitro or in vivo dose of a drug that causes 50% of the maximum possible inhibition for that drug |
| i.d. | Intradermal route of drug administration |
| IF | Immunofluorescence |
| i.g. | Intragastric route of administration |
| IHC | Immunohistochemistry |
| i.m. | Intramuscular route of drug administration |
| IMDM | Iscove's modification of DMEM |
| IMEM | improved minimum essential medium |
| In vitro | Taking place in a test-tube, culture dish or elsewhere outside a living organism |
| In vivo | Taking place in a living organism |
| i.p. | Intraperitoneal route of drug administration |
| IP | Immunoprecipitation |
| i.t. | Intrathecal route of drug administration |
| ITS | insulin, transferrin, selenium |
| i.v. | Intravenous route of drug administration |
| Kd | The dissociation constant for a radiolabeled drug determined by saturation analysis |
| Ki | The inhibition constant for a ligand, which denotes the affinity of the ligand for a receptor |
| LAH | lactalbumin hydrolysate |
| LSM | lymphocyte separation medium |
| MCL | Mantle cell lymphoma |
| MDS | Myelodysplastic syndromes |
| MEM | minimum essential medium |
| Met | L-methionine |
| MF | Myelofibrosis |
| Mg | magnesium |
| MM | Multiple myeloma |
| MTG | α-thioglycerol |
| NaHCO3 | sodium dicarbonate |
| NEAA | non-essential amino acid |
| NSCLC | Non-small cell lung cancers |
| NZ | New Zealand |
| PBS | phosphate buffered saline |
| pD2 | The negative logarithm of the EC50 or IC50 value |
| pEC50 | The negative logarithm of the EC50 value |
| pIC50 | The negative logarithm of the IC50 value |
| PF | protein-free |
| pKB | The negative logarithm of the KB value |
| pKd | The negative logarithm of the Kd value |
| pKi | The negative logarithm of the Ki value |
| p.o. | Oral (by mouth) route of drug administration |
| PR | phenol red |
| PROTAC | Proteolysis-targeting chimeras |
| RPMI | Roswell Park Memorial Institute |
| s.c. | Subcutaneous route of drug administration |
| s.c. | Subcutaneous route of drug administration |
| SF | serum-free |
| SNIPER | Specific and non-genetic inhibitor of apoptosis protein [IAP]-dependent protein eraser |
| SP | sodium pyruvate |
| TBS | tris buffered saline |
| USP | United States Pharmacopoeia |
| WB | Western blot |
| WFI | water for injection |
| WM | Waldenström's macroglobulinemia |
